Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines.
Cellics Therapeutics has raised $7.0M in total funding. The most recent round was Series B. The last funding was announced in February 2022.
Cellics Therapeutics's investors include CARB-X.
Cellics Therapeutics is headquartered in San Diego, United States.
Cellics is committed to saving lives and improving patients’ health using innovative biomimetic nanomedicines.
Cellics Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cellics Therapeutics — Funding & Investors." VCBacked, February 17, 2022, https://www.vcbacked.co/company/cellics-therapeutics. Accessed August 13, 2026.
VCBacked. (2022). Cellics Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/cellics-therapeutics
{{cite web |title=Cellics Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cellics-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated